Vicore Pharma Holding AB (publ)
VICO
Rank in Stocks
#14648
Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company,... Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.
Share Price
$1.10
Last synced: 2026-11-09
Market Cap
$310.91M
Change (1 day)
6.84%
Change (1 year)
3.18%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Vicore Pharma Holding AB (publ) (VICO)
Category
Healthcare
Operating Margin for Vicore Pharma Holding AB (publ) (VICO)
Operating Margin as of November 2026 TTM: -13,141.91%
According to Vicore Pharma Holding AB (publ)'s latest financial reports, its current operating margin (TTM) is -13,141.91%. At the end of 2025 the company had an operating margin of -11,905.82%.
Operating Margin history for Vicore Pharma Holding AB (publ) from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -13,141.91% | 10.38% |
| 2025 | -11,905.82% | 6,604.10% |
| 2024 | -177.59% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | -100.00% |
| 2018 | -8,716.54% | 535.02% |
| 2017 | -1,372.64% | 75.89% |
| 2016 | -780.40% | 44.30% |
| 2015 | -540.83% | 59.11% |
| 2014 | -339.91% | 275.09% |
| 2013 | -90.62% | 68.63% |
| 2012 | -53.74% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -99.99% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Vicore Pharma Holding AB (publ)'s operating margin
What is Vicore Pharma Holding AB (publ)'s operating margin?
Vicore Pharma Holding AB (publ)'s operating margin is -13,141.91%, as of Nov 2026.
What was Vicore Pharma Holding AB (publ)'s operating margin in 2025?
In 2025, Vicore Pharma Holding AB (publ)'s operating margin was -11,905.82%, compared with -177.59% in 2024.
How has Vicore Pharma Holding AB (publ)'s operating margin changed since 2020?
From 2020 to 2025, Vicore Pharma Holding AB (publ)'s operating margin was highest in 2023 (0.00%) and lowest in 2025 (-11,905.82%).
How does Vicore Pharma Holding AB (publ)'s operating margin compare with similar companies?
Vicore Pharma Holding AB (publ)'s operating margin (-13,141.91%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.